Stock Events

Stock Events

Silence Therapeutics 

$14.64
19
-$0.15-1.01% 17:59 Today

Statistics

Day High
14.79
Day Low
14.42
52W High
17.58
52W Low
4.19
Volume
223,115
Avg. Volume
991,353
Mkt Cap
909.94M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

5MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
-0.43
-0.28
-0.13
0.02
Expected EPS
-0.43
Actual EPS
-0.27

Financials

-15,851.88%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
559,000Revenue
-88.61MNet Income

Analyst Ratings

53.50Average Price Target
The highest estimate is 75.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SLN. It's not an investment recommendation.
Shell
3
SHEL.LSE
Lilly(Eli) &
3
LLY
Tesla
2
TSLA
Amazon
2
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with Silence Therapeutics' RNA-based treatments.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, making it a direct competitor in the RNA space.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap11.99B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, similar to Silence Therapeutics' approach.
Moderna
MRNA
Mkt Cap55.09B
Moderna is known for its mRNA technology platform, which, while primarily focused on vaccines, competes in the broader RNA-based therapeutic space.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech SE, though famous for its COVID-19 vaccine, also works on mRNA-based therapies, placing it in competition with Silence Therapeutics.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is engaged in gene editing, a different but competing approach to Silence Therapeutics' gene silencing techniques.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the gene editing space, offering a competing technology to Silence Therapeutics' RNA interference methods.

About

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Show more...
CEO
Iain Gladstone Ross
Employees
88
Country
United Kingdom
ISIN
US82686Q1013
WKN
000A2QB4J

Listings

STU
DE
XRP2.STU
MU
DE
XRP2.MU
OTC Link
US
SLNCF
XNAS
US
SLN

0 Comments

Share your thoughts

FAQ

What is Silence Therapeutics stock price today?▼
The current price of SLN is $14.64 USD — it has decreased by -1.01% in the past 24 hours. Watch Silence Therapeutics stock price performance more closely on the chart.
What is Silence Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Silence Therapeutics stocks are traded under the ticker SLN.
Is Silence Therapeutics stock price growing?▼
SLN stock has risen by +9.43% compared to the previous week, the month change is a +31.47% rise, over the last year Silence Therapeutics has showed a +180.78% increase.
What is Silence Therapeutics market cap?▼
Today Silence Therapeutics has the market capitalization of 909.94M
What were Silence Therapeutics earnings last quarter?▼
SLN earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.43 USD resulting in a +37.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Silence Therapeutics revenue for the last year?▼
Silence Therapeutics revenue for the last year amounts to 559,000 USD.
What is Silence Therapeutics net income for the last year?▼
SLN net income for the last year is -88.61M USD.
How many employees does Silence Therapeutics have?▼
As of September 04, 2026, the company has 88 employees.
In which sector is Silence Therapeutics located?▼
Silence Therapeutics operates in the Health & Wellness sector.
When did Silence Therapeutics complete a stock split?▼
Silence Therapeutics has not had any recent stock splits.
Where is Silence Therapeutics headquartered?▼
Silence Therapeutics is headquartered in LONDON, United Kingdom.